Investigational New Drug Application for ATI-2138 Allowed
WAYNE, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it will host a virtual R&D Day on Tuesday, December 7, 2021 from 10:00 a.m. to 12:00 p.m. ET.
“We are pleased to announce that the IND application for ATI-2138, an investigational oral small molecule ITK/TXK/JAK3 (ITJ) inhibitor, for the treatment of psoriasis has been allowed by the U.S. Food and Drug Administration and we are very excited about our plans to progress this third novel compound from our proprietary KINect® drug discovery platform into clinical development,” said Dr. Neal Walker, President & CEO of Aclaris. “We look forward to providing more details about this clinical program and our other pipeline assets at our upcoming virtual R&D Day in early December.”
The virtual R&D Day, intended for investors and analysts, will include the following topics:
- Zunsemetinib (ATI-450), an Investigational Oral MK2 Inhibitor
- ATI-2231, an Investigational Oral MK2 Inhibitor
- ATI-2138, an Investigational ITJ Inhibitor
- Oral Gut-restricted Discovery Program
Conference Call and Webcast
Management will host the event via conference call and webcast, with an accompanying slide presentation. To participate in the call, please dial (844) 776-7782 (domestic) or (661) 378-9535 (international) and reference conference ID 7675751. A webcast of the event may be accessed through the “Events” page of the “Investors” section of Aclaris’ website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Aclaris’ current beliefs and expectations. These forward-looking statements include Aclaris’ plans for the clinical development of ATI-2138. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Aclaris’ reliance on third parties over which it may not always have full control, Aclaris’ ability to enter into strategic partnerships on commercially reasonable terms, the uncertainty regarding the COVID-19 pandemic and other risks and uncertainties that are described in the Risk Factors section of Aclaris’ Annual Report on Form 10-K for the year ended December 31, 2020 and other filings Aclaris makes with the U.S. Securities and Exchange Commission from time to time. These documents are available under the “SEC Filings” page of the “Investors” section of Aclaris’ website at www.aclaristx.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
Aclaris Contact
